Table 1 Characteristics of patients
Number of pt. 86 | Baseline | Follow up | p-value |
|---|---|---|---|
Age | 61 [55–65] | 65 [60–71] | |
Gender (Male/Female) | 47/39 | 47/39 | |
MATTIS DEMENTIA RATING SCALE (MDRS) | 141 [138-142] | 141 [138-142] | 0.7 |
FRONTAL ASSESSMENT BATTERY (FAB) | 17 [16–18] | 17 [16–18] | 0.55 |
MDS-UPDRS I | 8.3 (5.0) | 10.7 (5.3) | <0.001 |
MDS-UPDRS II | 7.7 (4.9) | 10.0 (4.8) | <0.001 |
MDS-UPDRS III | 27 (9.3) | 31.0 (9.5) | <0.001 |
MDS-UPDRS IV | 0 | 2 [0-5] | <0.001 |
Non-motor fluctuation ON [N. ≥ 1] | 0 [0-0] [1] | 0 [0–0] [10] | |
Non-motor fluctuations OFF [N. ≥ 1] | 0 [0-0] [4] | 0 [0–1] [26] | |
Total Levodopa equivalent dose | 483 [350–700] | ||
Total dopamine agonists equivalent dose | 150 [0–240] | ||
Rasagiline (N.) | 20 | 49 | |
Benzodiazepine (N.) | 10 | 12 | |
Antidepressant (N.) | 11 | 11 | |
Clozapine (N.) | 0 | 2 |
